In vitro, niclosamide in combination with PD-1/programmed cell death ligand 1 (PD-L1) antibody has a synergistic anti-tumor effect in non-small cell lung cancer models through decreasing PD-L1 expression and promoting cytotoxic T-cell activity [31]. Here, CD274 is linked to neoplasm.